Fetal Surfactant Production: Timeline & Clinical Significance

Pulmonary surfactant (dipalmitoylphosphatidylcholine-rich lipoprotein) reduces alveolar surface tension, preventing atelectasis.

Developmental Timeline

Gestational AgeSurfactant Milestone
~20–24 weeksType II pneumocytes appear; lamellar bodies visible; minimal phospholipid synthesis
24–28 weeksOnset of measurable surfactant production; L/S ratio <2.0
30–34 weeksAccelerated synthesis; L/S ratio approaches 2.0; PG appears
≥35 weeksMature profile: L/S ratio ≥2.0, phosphatidylglycerol (PG) present
Term (37–40 wks)Full surfactant pool; adequate for extrauterine transition

Clinical Assessment

  • Amniocentesis: L/S ratio, PG, fluorescence polarization (TDx FLM II) – guides delivery timing in high-risk pregnancies.
  • Corticosteroids (betamethasone 12 mg IM q24h ×2) → ↑ surfactant synthesis 48 hrs post-dose; maximal effect 7 days; give 24 hrs–7 days before anticipated preterm birth (24–34 wks).

Respiratory Distress Syndrome (RDS)

  • Surfactant deficiency → alveolar collapse → ventilation-perfusion mismatch → hypoxemia.
  • Incidence: <30 wks ~60%, 34–36 wks ~5%, term <1%.
  • Exogenous surfactant (beractant, poractant alfa, calfactant) via endotracheal tube – lifesaving.

Surfactant production begins ~24 weeks; maturity typically by 35 weeks; corticosteroids accelerate maturation.

Baby Health - Related Articles